Oral contraceptive formulation and ovarian cysts: FDA committee finds no increased risk of follicular enlargement with low-dose monophasic or triphasic preparations.
D000569:Americas; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D019049:Developed Countries; D004194:Disease; D005193:Family Planning Services; D006077:Government Agencies; D009656:North America; D009938:Organizations; D010048:Ovarian Cysts; D014481:United States
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal
Americas; Contraception; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents--administraction and dosage; Contraceptive Methods; Developed Countries; Diseases; Family Planning; Government Agencies; Literature Review; North America; Northern America; Oral Contraceptives; Oral Contraceptives, Combined; Oral Contraceptives, Low-dose; Oral Contraceptives, Phasic; Organizations; Ovarian Cysts; United States